LoadingLoadingLoadingNet selling: insiders sold $275K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (2)
D.E. Shaw
$167.2M
added
Two Sigma
$84.4M
added
Sells/Trims (1)
Citadel
$34.4M
trimmed
Sells (1)
Charney Laurence N
$275K
sold
Top-trader positions in TGTX could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 3, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.44 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 21, 2026
EPS expected
$0.19 to $0.35
Revenue expected
8 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 3, 2026 | $0.05 / $0.44Yahoo Finance | -88.60% miss | $240.3M No estimate | Unavailable |
| Mar 31, 2026 | May 6, 2026 | $0.18 / $0.28Yahoo Finance | -35.09% miss | $204.9M No estimate | Unavailable |
| Dec 31, 2025 | Feb 26, 2026 | $0.14 / $0.33Yahoo Finance | -57.48% miss | $192.6M No estimate | Unavailable |
| Sep 30, 2025 | Nov 3, 2025 | $0.16 / $0.22Yahoo Finance | -26.30% miss | $161.7M No estimate | Unavailable |
| Jun 30, 2025 | Aug 4, 2025 | $0.17 / $0.29Alpha Vantage | -41.38% miss | $141.1M No estimate | Unavailable |
| Mar 31, 2025 | May 5, 2025 | $0.03 / $0.17Alpha Vantage | -82.35% miss | $120.9M No estimate | Unavailable |
| Dec 31, 2024 | Mar 3, 2025 | $0.15 / $0.09Alpha Vantage | +$0.06 beat | $108.2M No estimate | Unavailable |
| Sep 30, 2024 | Nov 4, 2024 | $0.02 / $0.03Alpha Vantage | -$0.01 miss | $83.9M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $161.7M | $192.6M | $204.9M | $240.3M |
| Cost of what it sold | $28.2M | $38.1M | $33.5M | $41.2M |
| Gross profit | $133.6M | $154.4M | $171.4M | $199.1M |
| What it spent | ||||
| Research and development | $40.9M | $41.2M | $48.4M | $95.3M |
| Sales and admin | $63.3M | $62.7M | $88.2M | $82.1M |
| Total operating expenses | $104.2M | $103.9M | $136.6M | $177.5M |
| What was left | ||||
| Operating profit | $29.4M | $50.5M | $34.8M | $21.7M |
| Interest on debt | $6.7M | $6.5M | $7.7M | $16.6M |
| Profit before tax | $25.9M | $45.1M | $20.4M | $10.2M |
| Tax | -$365.0M | $22.1M | $586.0K | $2.5M |
| Net profit | $390.9M | $23.0M | $19.8M | $7.8M |
| EBITDA | $32.7M | $51.7M | $28.1M | $21.8M |
This stock's price action is mixed.
Trend
Mixed
40 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
BullishOct 21TG Therapeutics reports seven-year BRIUMVI disability and safety findings
Leans bullishOct 21TG Therapeutics, Inc. (TGTX) Stock Forecasts
NeutralOct 15TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
BullishOct 14TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
BullishOct 13TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
BullishOct 13TG Therapeutics Inc (NKB2.DU) Stock Price, News, Quote & History
NeutralOct 13TG Therapeutics (TGTX) Reports Five-Year Study Showing BRIUMVI's Superior Disability Progression Outcomes in RMS
BullishOct 1210 macro signals shaping TGTX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results